Annette C Reboli

Summary

Affiliation: Cooper University Hospital
Country: USA

Publications

  1. ncbi Anidulafungin versus fluconazole for invasive candidiasis
    Annette C Reboli
    University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School and Cooper University Hospital, Camden, NJ 08103, USA
    N Engl J Med 356:2472-82. 2007
  2. ncbi Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients
    Annette C Reboli
    University of Medicine and Dentistry of New Jersey UMDNJ Robert Wood Johnson Medical School, Camden, New Jersey, USA
    Pharmacoeconomics 29:705-17. 2011
  3. ncbi Anidulafungin: a new echinocandin for candidal infections
    Pola de la Torre
    University of Medicine and Dentistry of New Jersey, Division of Infectious Diseases, Cooper University Hospital, Robert Wood Johnson Medical School, NJ, USA
    Expert Rev Anti Infect Ther 5:45-52. 2007
  4. ncbi Anidulafungin: a novel echinocandin for candida infections
    Pola de la Torre
    Division of Infectious Diseases, Cooper University Hospital, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, NJ, USA
    Future Microbiol 3:593-601. 2008
  5. ncbi Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome
    Annette C Reboli
    Division of Infectious Diseases, Cooper Medical School of Rowan University, 2 Aquarium Drive, Suite 305, Camden, NJ 08103, USA
    BMC Infect Dis 11:261. 2011
  6. ncbi A comparative evaluation of properties and clinical efficacy of the echinocandins
    Rose Kim
    Cooper University Hospital UMDNJ Robert Wood Johnson Medical School Education and Research Building, Division of Infectious Diseases, Department of Medicine, Camden, NJ 08103, USA
    Expert Opin Pharmacother 8:1479-92. 2007
  7. ncbi Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis
    Peter G Pappas
    Div of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL 35294 0006, USA
    Clin Infect Dis 45:883-93. 2007
  8. ncbi A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40
    Mitchell Goldman
    Indiana University School of Medicine, Division of Infectious Diseases, Wishard Memorial Hospital, Indianapolis, IN 46202, USA
    Clin Infect Dis 41:1473-80. 2005
  9. ncbi Anidulafungin: a drug evaluation of a new echinocandin
    Jomy M Joseph
    University of the Sciences in Philadelphia, Philadelphia College of Pharmacy, Philadelphia, PA 19104, USA
    Expert Opin Pharmacother 9:2339-48. 2008
  10. ncbi Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt
    Elias J Anaissie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Clin Infect Dis 43:1031-9. 2006

Detail Information

Publications10

  1. ncbi Anidulafungin versus fluconazole for invasive candidiasis
    Annette C Reboli
    University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School and Cooper University Hospital, Camden, NJ 08103, USA
    N Engl J Med 356:2472-82. 2007
    ..Anidulafungin, a new echinocandin, has potent activity against candida species. We compared anidulafungin with fluconazole in a randomized, double-blind, noninferiority trial of treatment for invasive candidiasis...
  2. ncbi Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients
    Annette C Reboli
    University of Medicine and Dentistry of New Jersey UMDNJ Robert Wood Johnson Medical School, Camden, New Jersey, USA
    Pharmacoeconomics 29:705-17. 2011
    ..Resource use and cost considerations are important in selecting appropriate treatment but little information is available on the economic implications of using echinocandins in this setting...
  3. ncbi Anidulafungin: a new echinocandin for candidal infections
    Pola de la Torre
    University of Medicine and Dentistry of New Jersey, Division of Infectious Diseases, Cooper University Hospital, Robert Wood Johnson Medical School, NJ, USA
    Expert Rev Anti Infect Ther 5:45-52. 2007
    ..Its mechanism of action, which differs from other classes of antifungals, should prevent cross-resistance with azoles and polyenes...
  4. ncbi Anidulafungin: a novel echinocandin for candida infections
    Pola de la Torre
    Division of Infectious Diseases, Cooper University Hospital, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, NJ, USA
    Future Microbiol 3:593-601. 2008
    ..Cross resistance with other classes of antifungals is not a concern as it possesses a unique mechanism of action...
  5. ncbi Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome
    Annette C Reboli
    Division of Infectious Diseases, Cooper Medical School of Rowan University, 2 Aquarium Drive, Suite 305, Camden, NJ 08103, USA
    BMC Infect Dis 11:261. 2011
    ..We sought to better understand the factors associated with the enhanced efficacy of anidulafungin and hypothesized that intrinsic properties of the antifungal agents contributed to the treatment differences...
  6. ncbi A comparative evaluation of properties and clinical efficacy of the echinocandins
    Rose Kim
    Cooper University Hospital UMDNJ Robert Wood Johnson Medical School Education and Research Building, Division of Infectious Diseases, Department of Medicine, Camden, NJ 08103, USA
    Expert Opin Pharmacother 8:1479-92. 2007
    ..Combination therapy with echinocandins plus other licensed antifungal therapy shows promise in treating invasive aspergillosis. This article will explore the similarities and differences among the echinocandins...
  7. ncbi Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis
    Peter G Pappas
    Div of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL 35294 0006, USA
    Clin Infect Dis 45:883-93. 2007
    ..The echinocandins have potent fungicidal activity against most Candida species, but there are few data comparing the safety and efficacy of echinocandins in the treatment of invasive candidiasis...
  8. ncbi A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40
    Mitchell Goldman
    Indiana University School of Medicine, Division of Infectious Diseases, Wishard Memorial Hospital, Indianapolis, IN 46202, USA
    Clin Infect Dis 41:1473-80. 2005
    ..However, concerns exist with regard to the use of fluconazole prophylaxis and the risk of development of fluconazole treatment-refractory infections...
  9. ncbi Anidulafungin: a drug evaluation of a new echinocandin
    Jomy M Joseph
    University of the Sciences in Philadelphia, Philadelphia College of Pharmacy, Philadelphia, PA 19104, USA
    Expert Opin Pharmacother 9:2339-48. 2008
    ..Over the past two decades, the frequency and type of invasive fungal infections have increased greatly and thus have driven the need for new antifungal agents. Anidulafungin is the newest addition to the echinocandin armamentarium...
  10. ncbi Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt
    Elias J Anaissie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Clin Infect Dis 43:1031-9. 2006